D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 90 Citations 43,570 361 World Ranking 6014 National Ranking 282

Overview

What is she best known for?

The fields of study she is best known for:

  • Cancer
  • Internal medicine
  • Breast cancer

Her scientific interests lie mostly in Breast cancer, Internal medicine, Oncology, Neoadjuvant therapy and Cancer. Her Breast cancer research is multidisciplinary, incorporating elements of Surgery, Radiation therapy, Gynecology and Hazard ratio. In general Internal medicine, her work in Chemotherapy, Trastuzumab, Taxane and Cyclophosphamide is often linked to Carboplatin linking many areas of study.

Her Oncology study combines topics from a wide range of disciplines, such as Clinical trial, Pathology, Anthracycline, Capecitabine and Tumor-infiltrating lymphocytes. Her studies in Neoadjuvant therapy integrate themes in fields like Bevacizumab, Clinical research, Adjuvant and Docetaxel. Sibylle Loibl has included themes like Cancer research and Carcinoma in her Cancer study.

Her most cited work include:

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (1828 citations)
  • Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis (1756 citations)
  • Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes (1376 citations)

What are the main themes of her work throughout her whole career to date?

Her main research concerns Internal medicine, Breast cancer, Oncology, Chemotherapy and Cancer. Her study in Internal medicine focuses on Neoadjuvant therapy, Trastuzumab, Clinical trial, Taxane and Triple-negative breast cancer. Her research in Breast cancer intersects with topics in Surgery, Pathology, Gynecology, Docetaxel and Hazard ratio.

In her research, Paclitaxel is intimately related to Epirubicin, which falls under the overarching field of Oncology. Her Chemotherapy study incorporates themes from Gastroenterology, Pathological, Capecitabine and Early breast cancer. Her Cancer study frequently draws connections to other fields, such as Cancer research.

She most often published in these fields:

  • Internal medicine (73.51%)
  • Breast cancer (70.20%)
  • Oncology (66.00%)

What were the highlights of her more recent work (between 2019-2021)?

  • Breast cancer (70.20%)
  • Internal medicine (73.51%)
  • Oncology (66.00%)

In recent papers she was focusing on the following fields of study:

Sibylle Loibl mostly deals with Breast cancer, Internal medicine, Oncology, Chemotherapy and Cancer. Her work in the fields of Breast cancer, such as Neoadjuvant therapy and Trastuzumab, overlaps with other areas such as Carboplatin. Sibylle Loibl regularly links together related areas like Gastroenterology in her Internal medicine studies.

Her research investigates the link between Oncology and topics such as Early breast cancer that cross with problems in Dose-dense chemotherapy. Sibylle Loibl studied Chemotherapy and Taxane that intersect with Anthracycline and Neutropenia. Her research in Cancer tackles topics such as Placebo which are related to areas like Anastrozole.

Between 2019 and 2021, her most popular works were:

  • Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. (196 citations)
  • Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial (52 citations)
  • ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. (50 citations)

In her most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Breast cancer

Her primary scientific interests are in Internal medicine, Breast cancer, Oncology, Neoadjuvant therapy and Chemotherapy. Her study involves Randomized controlled trial, Trastuzumab, Cancer, Predictive biomarker and Stromal tumor, a branch of Internal medicine. Her Breast cancer research includes themes of Clinical trial, Phases of clinical research, Adverse effect and Hazard ratio.

Her work carried out in the field of Oncology brings together such families of science as Regimen, Metastatic breast cancer, Palbociclib, Biomarker and Triple-negative breast cancer. Her Neoadjuvant therapy research includes elements of Gastroenterology, Multivariate analysis, Pathological and Cumulative incidence. Her Chemotherapy study combines topics from a wide range of disciplines, such as Guideline, Endocrine therapy, Targeted therapy, Recurrence risk and Pooled analysis.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

A Goldhirsch;E P Winer;A S Coates;R D Gelber.
Annals of Oncology (2013)

2956 Citations

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Patricia Cortazar;Lijun Zhang;Michael Untch;Keyur Mehta.
The Lancet (2014)

2460 Citations

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

Gunter von Minckwitz;Michael Untch;Jens-Uwe Blohmer;Serban D. Costa.
Journal of Clinical Oncology (2012)

1945 Citations

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

R. Salgado;R. Salgado;C. Denkert;S. Demaria;N. Sirtaine.
Annals of Oncology (2015)

1424 Citations

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

Carsten Denkert;Sibylle Loibl;Aurelia Noske;Marc Roller.
Journal of Clinical Oncology (2010)

1332 Citations

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

Nicholas C. Turner;Jungsil Ro;Fabrice André;Sherene Loi.
The New England Journal of Medicine (2015)

1198 Citations

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

S. Loi;S. Loi;S. Michiels;S. Michiels;R. Salgado;N. Sirtaine.
Annals of Oncology (2014)

924 Citations

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

Carsten Denkert;Gunter von Minckwitz;Jan C. Brase;Bruno V. Sinn.
Journal of Clinical Oncology (2015)

857 Citations

Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update

Manfred Kaufmann;Gabriel N. Hortobagyi;Aron Goldhirsch;Suzy Scholl.
Journal of Clinical Oncology (2006)

806 Citations

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

Gunter von Minckwitz;Andreas du Bois;Marcus Schmidt;Nicolai Maass.
Journal of Clinical Oncology (2009)

778 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Sibylle Loibl

Giuseppe Curigliano

Giuseppe Curigliano

European Institute of Oncology

Publications: 141

Giuseppe Viale

Giuseppe Viale

European Institute of Oncology

Publications: 126

Sherene Loi

Sherene Loi

Peter MacCallum Cancer Centre

Publications: 118

Roger L. Milne

Roger L. Milne

Cancer Council Victoria

Publications: 112

Nadia Harbeck

Nadia Harbeck

Ludwig-Maximilians-Universität München

Publications: 110

Peter A. Fasching

Peter A. Fasching

University of Erlangen-Nuremberg

Publications: 109

Andreas Schneeweiss

Andreas Schneeweiss

German Cancer Research Center

Publications: 105

Graham G. Giles

Graham G. Giles

University of Melbourne

Publications: 97

Martine Piccart

Martine Piccart

Université Libre de Bruxelles

Publications: 94

Carsten Denkert

Carsten Denkert

Philipp University of Marburg

Publications: 91

Eric P. Winer

Eric P. Winer

Harvard University

Publications: 86

Javier Cortes

Javier Cortes

Vall d'Hebron Hospital Universitari

Publications: 85

Marco Colleoni

Marco Colleoni

European Institute of Oncology

Publications: 84

Michael Untch

Michael Untch

University of Miami

Publications: 81

Hope S. Rugo

Hope S. Rugo

University of California, San Francisco

Publications: 76

Jenny Chang-Claude

Jenny Chang-Claude

German Cancer Research Center

Publications: 76

Trending Scientists

Qiang Li

Qiang Li

Virginia Tech

Hidenori Akiyama

Hidenori Akiyama

Kumamoto University

Xiaojun Liao

Xiaojun Liao

China Agricultural University

Stephen P. Cramer

Stephen P. Cramer

Search for Extraterrestrial Intelligence

Richard E. Palmer

Richard E. Palmer

Swansea University

Bruno Garin-Bastuji

Bruno Garin-Bastuji

French Agency for Food, Environmental and Occupational Health & Safety

Salvatore Valitutti

Salvatore Valitutti

Federal University of Toulouse Midi-Pyrénées

David Sklan

David Sklan

Hebrew University of Jerusalem

Christopher M. Raymond

Christopher M. Raymond

University of Helsinki

Simon Paul Liversedge

Simon Paul Liversedge

University of Central Lancashire

Setsuo Hirohashi

Setsuo Hirohashi

National Cancer Research Institute, UK

David T. W. Jones

David T. W. Jones

German Cancer Research Center

Anne Rasmussen

Anne Rasmussen

University of Copenhagen

Matt Visser

Matt Visser

Victoria University of Wellington

Zahid Hussain

Zahid Hussain

Lawrence Berkeley National Laboratory

Something went wrong. Please try again later.